Boiron SA (EPA:BOI)

Market Cap	487.88M +21.4%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +188.0%
Shares Out	17.36M
PE Ratio	14.95
Forward PE	n/a
Dividend	1.35 (4.86%)
Ex-Dividend Date	Jun 3, 2026

Volume	4,891
Open	27.60
Previous Close	27.80
Day's Range	27.20 - 28.10
52-Week Range	20.85 - 32.25
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,634
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error